Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill® Daily Oral Contraceptive for OTC Use
Details : Opill (norgestrel) is a progestin-only daily oral contraceptive, available for over-the-counter (OTC) is used by females of reproductive potential to prevent pregnancy.
Product Name : Opill
Product Type : Hormone
Upfront Cash : Inapplicable
October 05, 2023
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves First Nonprescription Daily Oral Contraceptive
Details : Opill (norgestrel) tablet for nonprescription use to prevent pregnancy the first daily oral contraceptive approved for use in the U.S. without a prescription.
Product Name : Opill
Product Type : Hormone
Upfront Cash : Inapplicable
July 13, 2023
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Perrigo Announces U.S. FDA Approval for Nicotine Coated Mint Lozenge
Details : U.S. Food and Drug Administration approved OTC, nicotine coated mint lozenges, works by reducing withdrawal symptoms in consumers who are trying to quit smoking.
Product Name : Nicorette-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 16, 2023
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Opill® is a progestin-only daily oral birth control pill (also referred to as a mini pill or non-estrogen pill), which prevents conception by suppressing ovulation.
Product Name : Opill
Product Type : Hormone
Upfront Cash : Inapplicable
March 28, 2023
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Perrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil® Dual Action Tablets
Details : Acetaminophen and Ibuprofen acts by inhibiting cyclooxygenases (COX-1 and COX-2), and thus prostaglandins, which are produced by the body in response to injury and inflammation.
Product Name : Acetaminophen/Ibuprofen-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2023
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Opill® is a progestin-only daily birth control pill (also referred to as a mini pill or non-estrogen pill). If approved, Opill® would be the first ever daily birth control pill available OTC—without a prescription—in the U.S.
Product Name : Opill
Product Type : Hormone
Upfront Cash : Inapplicable
October 26, 2022
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omeprazole Magnesium
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Perrigo Announces U.S. FDA Approval For Omeprazole Magnesium Delayed-Release Mini Capsules
Details : Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC),represents a first-to-market mini capsule form of omeprazole, which is indicated for treatment of frequent heartburn.
Product Name : Omeprazole Magnesium-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Omeprazole Magnesium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Organon
Deal Size : Inapplicable
Deal Type : Inapplicable
Perrigo Announces U.S. Fda Approval For Otc Use Of Nasonex® 24hr Allergy
Details : The approval marks the first branded Rx-to-OTC switch for the company and paves the way for Nasonex® 24HR Allergy (mometasone furoate monohydrate 50mcg) to enter the OTC marketplace.
Product Name : Nasonex
Product Type : Steroid
Upfront Cash : Inapplicable
March 17, 2022
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Organon
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adapalene
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Altaris Capital Partners
Deal Size : $1,550.0 million
Deal Type : Divestment
Perrigo To Sell Generic Drugs Business for $1.55 Billion
Details : Adapalene Cream indicated for the topical treatment of acne vulgaris in Perrigo Topical Generic Rx Business.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $1,500.0 million
January 03, 2021
Lead Product(s) : Adapalene
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Altaris Capital Partners
Deal Size : $1,550.0 million
Deal Type : Divestment
Lead Product(s) : Benzoyl Peroxide
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Sol-Gel Technologies
Deal Size : Undisclosed
Deal Type : Agreement
Details : Consistent with Sol-Gel’s prior agreements, Perrigo will seek regulatory approval with the U.S. FDA for these generic product candidates. If approved by the FDA, Perrigo will lead the commercialization efforts for the generic product candidates in the ...
Product Name : Epsolay
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 29, 2020
Lead Product(s) : Benzoyl Peroxide
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Sol-Gel Technologies
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
